The purpose of this conference is to: 1) Disseminate current knowledge of the standard treatment of hairy cell leukemia (HCL), 2) Identify the evidence (or lack thereof) with which current treatment practices are based, 3) determine needs and opportunities for clinical research to improve HCL treatment, 4) disseminate results of newer diagnostic techniques, including flow cytometry, PCR and serum markers, to allow decreased reliance on bone marrow biopsy, 5) discuss recent advances in HCL biology, including the molecular characterization of HCL cells with implications for disease origination/prognosis, 6) discuss new treatments for relapse/refractory disease, including investigational agents 7) improve patient access to treatment and clinical trials, and 8) discuss the evolving activities of the HCL Consortium, including establishing a new HCL website to improve access to knowledge, care givers, treatment and clinical trials.

Dr. Robert Kreitman, 301-496-6947, kreitmar@mail.nih.gov

Please note that only physicians or researchers may register for this meeting. However, all attending, including speakers and poster presenters, should register. You will receive a copy of your registration submission. This does not mean that your registration has been accepted. If your registration is ultimately accepted, you will receive a second email.